Innate Pharma Doses First Patient in Trial Testing Avdoralimab as COVID-19 Treatment

Innate Pharma has dosed its first patient in a phase 2 trial of its investigational cancer treatment avdoralimab as a treatment for COVID-19 patients with severe pneumonia. 

The goal of the 108-patient trial is to increase the proportion of patients who no longer need to be hospitalized and to reduce dependence on ventilation in patients with pneumonia complicated by acute respiratory distress syndrome.

Avdoralimab is currently in phase 1 studies for treatment of solid tumors, including hepatocellular carcinoma and small-cell lung cancer.